LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.52 3.7

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.42

Max

2.57

Belangrijke statistieken
By Trading Economics
Inkomsten	-27M -17M
EPS	-0.125
Winstmarge	-2,366.017
Werknemers	23
EBITDA	-5.5M -18M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+117.55% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-19M 464M
Vorige openingsprijs	-1.18
Vorige sluitingsprijs	2.52

Nieuwssentiment

By Acuity

50%

138 / 344 Rangschikking in Healthcare

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2026, 21:33 UTC

Winsten

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mei 2026, 21:00 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mei 2026, 20:18 UTC

Winsten

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mei 2026, 23:49 UTC

Marktinformatie

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mei 2026, 23:39 UTC

Marktinformatie

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 mei 2026, 23:08 UTC

Marktinformatie

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mei 2026, 22:21 UTC

Marktinformatie

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mei 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mei 2026, 21:08 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mei 2026, 21:02 UTC

Winsten

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mei 2026, 20:59 UTC

Acquisities, Fusies, Overnames

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mei 2026, 20:55 UTC

Winsten

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 mei 2026, 20:48 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mei 2026, 20:45 UTC

Winsten

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mei 2026, 20:34 UTC

Acquisities, Fusies, Overnames

Webster Financial Stockholders Approve Sale to Banco Santander

27 mei 2026, 20:32 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mei 2026, 20:30 UTC

Winsten

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mei 2026, 20:30 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mei 2026, 20:22 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:16 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mei 2026, 20:13 UTC

Winsten

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

117.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.33 USD 117.55%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

138 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.